Raymond James & Associates Cassava Sciences Inc Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Cassava Sciences Inc stock. As of the latest transaction made, Raymond James & Associates holds 68,671 shares of SAVA stock, worth $1.82 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

68,671

Previous 76,959 10.77%

Holding current value

$1.82 Million

Previous $950,000 112.63%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	SELL	$9.57 - $35.08 $79,316 - $290,743	-8,288 Reduced 10.77%	68,671 $2.02 Million
Q2 2024 Jul 19, 2024	BUY	$12.35 - $26.11 $11,263 - $23,812	912 Added 1.2%	76,959 $950,000
Q1 2024 Apr 22, 2024	BUY	$18.44 - $26.41 $35,958 - $51,499	1,950 Added 2.63%	76,047 $1.54 Million
Q4 2023 Jan 16, 2024	BUY	$12.64 - $30.11 $7,141 - $17,012	565 Added 0.77%	74,097 $1.67 Million
Q3 2023 Oct 24, 2023	BUY	$16.64 - $25.32 $201,826 - $307,106	12,129 Added 19.75%	73,532 $1.22 Million
Q2 2023 Jul 25, 2023	SELL	$21.59 - $27.88 $70,404 - $90,916	-3,261 Reduced 5.04%	61,403 $1.51 Million
Q1 2023 Apr 14, 2023	BUY	$23.46 - $36.44 $84,268 - $130,892	3,592 Added 5.88%	64,664 $1.56 Million
Q4 2022 Feb 08, 2023	BUY	$27.82 - $44.16 $66,378 - $105,365	2,386 Added 4.07%	61,072 $1.8 Million
Q3 2022 Oct 25, 2022	BUY	$16.33 - $51.06 $223,002 - $697,275	13,656 Added 30.33%	58,686 $2.45 Million
Q2 2022 Aug 12, 2022	SELL	$17.22 - $38.47 $147,695 - $329,957	-8,577 Reduced 16.0%	45,030 $1.27 Million
Q1 2022 May 11, 2022	BUY	$32.6 - $53.05 $323,261 - $526,043	9,916 Added 22.7%	53,607 $1.99 Million
Q4 2021 Feb 08, 2022	BUY	$36.77 - $90.91 $206,059 - $509,459	5,604 Added 14.71%	43,691 $1.91 Million
Q3 2021 Nov 02, 2021	BUY	$41.79 - $135.3 $833,501 - $2.7 Million	19,945 Added 109.94%	38,087 $2.36 Million
Q2 2021 Aug 11, 2021	SELL	$32.15 - $89.72 $80,021 - $223,313	-2,489 Reduced 12.06%	18,142 $1.55 Million
Q1 2021 May 14, 2021	BUY	$7.09 - $87.95 $146,273 - $1.81 Million	20,631 New	20,631 $927,000

Others Institutions Holding SAVA

# of Institutions

207

Shares Held

14M

Call Options Held

2.98M

Put Options Held

6.57M

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $1.06B
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Cassava Sciences Inc Transaction History